NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next...

Full description

Bibliographic Details
Main Authors: Estela Sánchez‐Herrero, Roberto Serna‐Blasco, Vadym Ivanchuk, Rosario García‐Campelo, Manuel Dómine Gómez, José M. Sánchez, Bartomeu Massutí, Noemi Reguart, Carlos Camps, Sandra Sanz‐Moreno, Silvia Calabuig‐Fariñas, Eloísa Jantus‐Lewintre, Magdalena Arnal, Dietmar Fernández‐Orth, Virginia Calvo, Víctor González‐Rumayor, Mariano Provencio, Atocha Romero
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Molecular Oncology
Subjects:
ALK‐TKI
EML4‐ALK
liquid biopsy
NGS
NSCLC
Online Access:https://doi.org/10.1002/1878-0261.13033

Internet

https://doi.org/10.1002/1878-0261.13033

Similar Items